Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million
By Dr. Matthew Watson
WOBURN, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has received proceeds of approximately $3.8 million from the exercise of 472,099 warrants exercised between January 1, 2021 and February 16, 2021, and the Company has issued to investors 472,099 shares of common stock in exchange for the exercised warrants. The warrants were issued to investors pursuant to a public offering that closed on November 19, 2019. Since November 19, 2019, a total of 679,395 warrants issued in the public offering have been exercised for total proceeds of $5.4 million. The Series A and Series B warrants issued in the November 2019 public offering are exercisable at $8.00 per share and have expiration dates of May 19, 2022 and May 19, 2027, respectively.
View original post here:
Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million
Related Post
- Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - February 19th, 2021
- Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - February 19th, 2021
- Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference - February 19th, 2021
- Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol... - February 19th, 2021
- Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021 - February 19th, 2021
- BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report® - February 19th, 2021
- BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i... - February 19th, 2021
- Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA - February 19th, 2021
- Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates - February 19th, 2021
- Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform - February 19th, 2021
- Assembly Bio Announces Upcoming Investor Events - February 19th, 2021
- RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 19th, 2021
- Intercept to Present at Upcoming Investor Conferences - February 19th, 2021
- CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology - February 19th, 2021
- Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan - February 19th, 2021
- Information expressed in the public domain by the Repharm Group is deceptive and contradictory - February 19th, 2021
- Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on... - February 19th, 2021
- Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 - February 19th, 2021
- Ayala Pharmaceuticals Announces $25 Million Strategic Financing - February 19th, 2021
- Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update - February 17th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- Lumos Pharma Announces Changes to its Board of Directors - February 17th, 2021
- Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference - February 17th, 2021
- Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels - February 17th, 2021
- Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - February 17th, 2021
- Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - February 17th, 2021
- MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021 - February 17th, 2021
- Aleafia Health Announces $15 Million Bought Deal Offering of Units - February 17th, 2021
- Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side - February 17th, 2021
- ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome - February 17th, 2021
- Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference - February 17th, 2021
- ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference - February 17th, 2021
- Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million - February 17th, 2021
- Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities... - February 17th, 2021
- Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease - February 17th, 2021
- Vistin Pharma ASA: Invitation to Q4 2020 conference call - February 14th, 2021
- Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine - February 14th, 2021
- Vericel Announces Termination of Shareholder Rights Agreement - February 14th, 2021
- Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - February 14th, 2021
- Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021 - February 14th, 2021
- Cronos Group Inc. to Hold 2020 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2021 - February 14th, 2021
- Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day - February 14th, 2021
- Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering - February 14th, 2021
- Delisting of AS „Grindeks” shares from the Baltic Main list - February 14th, 2021
- Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021 - February 14th, 2021
- Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line - February 14th, 2021
- New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three... - February 14th, 2021
- Radius Health, Inc. Provides Abaloparatide Business Update - February 14th, 2021
- Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the... - February 14th, 2021
- Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium... - February 14th, 2021
- FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced... - February 14th, 2021
- Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares - February 14th, 2021
- Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx - February 14th, 2021
- Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock - February 14th, 2021
- Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn - February 14th, 2021
- Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 - February 11th, 2021
- Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium - February 11th, 2021
- Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021 - February 11th, 2021
- X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call and Webcast on March 4, 2021 - February 11th, 2021
- VYNE Therapeutics Announces Reverse Stock Split - February 11th, 2021
- BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice President - February 11th, 2021
- aTyr Pharma Announces New tRNA Synthetase Discovery Programs - February 11th, 2021
- Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25 - February 11th, 2021
- electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting... - February 11th, 2021
- scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 11th, 2021
- Syneos Health Identifies Important Drivers of Change Expected to Disrupt Healthcare - February 11th, 2021
- Albireo Presents Odevixibat Commercialization Road to $1 Billion - February 11th, 2021
- Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - February 11th, 2021
- Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions - February 11th, 2021
- Senti Bio to Participate in Upcoming Investor Conferences - February 11th, 2021
- Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space... - February 11th, 2021
- Gain Therapeutics Presents Positive Pre-Clinical Data Supportive of In Vitro Target Engagement for Gaucher Disease, GM1 Gangliosidosis and Morquio B... - February 11th, 2021
- ORYZON Announces FDA Orphan Drug Designation Granted to iadademstat for Treatment of Acute Myeloid Leukemia - February 11th, 2021
- WeedMD Inc. Announces Increase in Bought Deal Equity Financing to $17.5 Million - February 11th, 2021
- Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020 - February 11th, 2021
- One World Pharma Secures $3 Million Investment Commitment From ISIAH International - February 10th, 2021
Global News Feed
Comments Off on Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million |
February 19th, 2021
This author published 3712 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research